Pre-emptive drugs for schizophrenia show mixed results

05/1/2006 | NYTimes.com

Findings from the first long-term trial of the concept of prescribing drugs to young people at risk of schizophrenia, but not yet exhibiting the disorder, raised more questions than they answered, experts said. The study's lead author says there were only marginally significant positive results, while the weight gain involved in taking Eli Lilly's antipsychotic drug Zyprexa caused many participants to drop out of the study, skewing results.

View Full Article in:

NYTimes.com

Published in Brief:

SmartBrief Job Listings for Health Care